Arcutis Biotherapeutics Inc (NASDAQ: ARQT) has experienced a decline in its stock price by -1.72 compared to its previous closing price of 8.71. However, the company has seen a gain of 2.64% in its stock price over the last five trading days. zacks.com reported 2024-10-25 that Arcutis Biotherapeutics (ARQT) doesn’t possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is It Worth Investing in Arcutis Biotherapeutics Inc (NASDAQ: ARQT) Right Now?
The 36-month beta value for ARQT is also noteworthy at 1.17. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 2 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for ARQT is 101.69M, and at present, short sellers hold a 27.60% of that float. The average trading volume of ARQT on October 30, 2024 was 2.04M shares.
ARQT’s Market Performance
ARQT stock saw a decrease of 2.64% in the past week, with a monthly decline of -7.96% and a quarterly a decrease of -15.00%. The volatility ratio for the week is 5.20%, and the volatility levels for the last 30 days are 5.64% for Arcutis Biotherapeutics Inc (ARQT). The simple moving average for the last 20 days is -7.82% for ARQT’s stock, with a simple moving average of -5.79% for the last 200 days.
Analysts’ Opinion of ARQT
Many brokerage firms have already submitted their reports for ARQT stocks, with Jefferies repeating the rating for ARQT by listing it as a “Buy.” The predicted price for ARQT in the upcoming period, according to Jefferies is $15 based on the research report published on August 28, 2024 of the current year 2024.
Mizuho, on the other hand, stated in their research note that they expect to see ARQT reach a price target of $8, previously predicting the price at $4. The rating they have provided for ARQT stocks is “Buy” according to the report published on January 03rd, 2024.
Mizuho gave a rating of “Neutral” to ARQT, setting the target price at $4 in the report published on October 26th of the previous year.
ARQT Trading at -12.08% from the 50-Day Moving Average
After a stumble in the market that brought ARQT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -35.00% of loss for the given period.
Volatility was left at 5.64%, however, over the last 30 days, the volatility rate increased by 5.20%, as shares sank -10.37% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -1.04% lower at present.
During the last 5 trading sessions, ARQT rose by +2.64%, which changed the moving average for the period of 200-days by +135.16% in comparison to the 20-day moving average, which settled at $9.29. In addition, Arcutis Biotherapeutics Inc saw 165.02% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ARQT starting from Welgus Howard G., who sale 10,000 shares at the price of $9.26 back on Oct 01 ’24. After this action, Welgus Howard G. now owns 181,944 shares of Arcutis Biotherapeutics Inc, valued at $92,616 using the latest closing price.
Edwards Larry Todd, the SVP Chief Commercial Officer of Arcutis Biotherapeutics Inc, sale 3,725 shares at $10.01 during a trade that took place back on Oct 02 ’24, which means that Edwards Larry Todd is holding 136,635 shares at $37,295 based on the most recent closing price.
Stock Fundamentals for ARQT
Current profitability levels for the company are sitting at:
- -1.36 for the present operating margin
- 0.92 for the gross margin
The net margin for Arcutis Biotherapeutics Inc stands at -1.51. The total capital return value is set at -0.46. Equity return is now at value -148.92, with -51.93 for asset returns.
Based on Arcutis Biotherapeutics Inc (ARQT), the company’s capital structure generated 0.52 points at debt to capital in total, while cash flow to debt ratio is standing at -0.86. The debt to equity ratio resting at 1.1. The interest coverage ratio of the stock is -5.94.
Currently, EBITDA for the company is -239.22 million with net debt to EBITDA at -0.7. When we switch over and look at the enterprise to sales, we see a ratio of 8.51. The receivables turnover for the company is 3.04for trailing twelve months and the total asset turnover is 0.3. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.46.
Conclusion
In summary, Arcutis Biotherapeutics Inc (ARQT) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
